Reporter brief
Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial
What happened
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- No efficacy data are reported in the abstract, so whether fisetin reduces cartilage degeneration or improves joint symptoms cannot be determined.
- Sample size is not provided, preventing assessment of statistical power or whether findings could reflect chance variation.
- Phase I/II trials are preliminary; results do not establish clinically meaningful benefit in large populations.
Study design and sample
Rct; Human.
Not recorded.
- Design
- Rct
- Sample
- —
- Journal
- Steadman Philippon Research Institute
- Published
- Sep 19, 2024
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.